期刊
BIOLOGICAL PSYCHIATRY
卷 71, 期 11, 页码 1022-1025出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2011.11.006
关键词
GABA; glutamate/glutamine cycle; ketamine; magnetic resonance spectroscopy; medial prefrontal cortex; NMDA
资金
- National Institute of Mental Health [R01 MH081211, 1R01 MH095104]
- Merck Co., Inc.
- Abbott
- AstraZeneca
- Bristol-Myers Squibb
- Evotec
- Eli Lilly Co.
- Hoffman La-Roche
- Johnson Johnson
- Novartis
- Novum Pharmaceuticals
- Merck Co.
- Sunovion Pharmaceuticals
Ketamine has recently gained significant attention owing to its psychotomimetic and more recently discovered rapid antidepressant-like properties. H-1-[C-13]-nuclear magnetic resonance studies were employed to explore potential physiological processes underlying these unique effects. [1-C-13] glucose and [2-C-13] acetate-nuclear magnetic resonance ex vivo studies were performed on the medial prefrontal cortex (mPFC) and hippocampus of rats acutely treated with 30 mg/kg or 80 mg/kg ketamine and compared with saline-treated animals to determine the effects of ketamine on amino acid neurotransmitter cycling and glial metabolism. A subanesthetic, but not anesthetic, dose of ketamine significantly increased the percentage of C-13-enrichments of glutamate, gamma-aminobutyric acid, and glutamine in the mPFC of rats. Subanesthetic doses of ketamine increased mPFC amino acid neurotransmitter cycling, as well as neuronal and glial energy metabolism. These data add to previous reports suggesting increased mPFC levels of glutamate release, following the administration of subanesthetic doses of ketamine, are related to the drug's acute effects on cognition, perception, and mood.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据